Most small medical device companies develop innovative proprietary technology in hopes of unseating much larger rivals--on the theory that physicians care more about the effectiveness of the technology than who makes it. But Advanced Neuromodulation Systems sees things differently. Its main competition is device giant Medtronic, which not only leads in terms of market share, but has been a technology innovator. ANS's play: not to defeat Medtronic at its own game, but to carve out a lucrative part of the chronic pain management market under Medtronic's radar.
by David Cassak
It's one of the enduring myths of the medical device industry that small companies innovate and, out of innovation itself,...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
